ClinicalTrials.gg
Active, not recruitingNCT03809000STEELUpdated Dec 30, 2025Results posted

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

A Phase 2 interventional study of Radiation Therapy and Enzalutamide in Prostate Cancer, sponsored by RTOG Foundation, Inc.. Active, not recruiting at 108 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by RTOG Foundation, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
29th of 125
188 · median 52
Started
2019
with 6 others
Phase 2
65 of 125
8 open now
Primary completion
2023-04
later than 7 of 37 live
Registered
90th of 125
by date

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 29th largest by enrollment, is one of 7 that started in 2019, is one of 65 in phase 2, reaches primary completion later than 7 of the 37 other live ones, and was the 90th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free survival when enhanced ADT is used compared to standard ADT.

Read the detailed description

PRIMARY OBJECTIVE:

To determine whether, in men with post-prostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Post-prostatectomy
  • Enzalutamide
  • STEEL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologically (histologically) proven adenocarcinoma confirmed by prostatectomy performed within 10 years prior to registration and any type of radical prostatectomy is permitted, including retropubic, perineal, laparoscopic or robotically assisted.
  • Prostate-specific antigen (PSA) level (≥ 0.2 ng/mL) within 120 days prior to registration. Patients must have a PSA ≥ 0.2 ng/mL prior to starting ADT. For patients being followed by an ultrasensitive PSA assay, a serum PSA concentration of ≥ 0.10 ng/mL will be considered eligible.
  • GnRH analog may be started no more than 42 days prior study entry.
  • ≥ 9.0 g/dL, independent of transfusion and/or growth factors within 90 days prior to registration.
  • count ≥ 75,000 x 10\^9/µL independent of transfusion and/or growth factors within 90 days prior to registration.
  • At least 1 of the following aggressive features:

    • Gleason score of 8-10 (note any Gleason score is eligible)
    • Seminal vesicle invasion (SVI) (note any pT stage American Joint Committee on Cancer (AJCC) v8.0 is eligible but a pT stage

      ≥ pT3b is considered aggressive)

    • Locoregional node involvement at radical prostatectomy (RP) (pN1)
    • Persistently elevated PSA post-RP nadir (PEPP) defined as PSA > 0.1 ng/mL after radical prostatectomy
    • PSA ≥ 0.7 ng/mL
  • Serum albumin ≥ 3.0 g/dL within 90 days prior to registration
  • (GFR) ≥35 mL/min estimated by or measured directly by 24 hour urine creatinine within 90 days prior to registration.
  • Serum total ≤1.5 × (ULN) (Note: In subjects with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤1.5 × ULN, subject is eligible) within 90 days prior to registration.
  • (AST) or alanine aminotransferase (ALT) \<2.5 × ULN within 90 days prior to registration.
  • History and physical with (ECOG) Performance Status 0-1 or within 90 days prior to registration.

Exclusion criteria

Exclusion Criteria:

  • Definitive clinical or radiologic evidence of disease with the exception of locoregional lymph nodes.
  • Prior invasive (except non-melanomatous skin cancer carcinoma in situ of the male breast, penis, oral cavity, or stage Ta of the bladder, or stage I completely resected melanoma) unless disease free for a minimum of 2 years).
  • Prior systemic chemotherapy for the study cancer. Note: prior chemotherapy for a different cancer is allowable.
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
  • History of any of the following:

    • Documented inflammatory bowel disease
    • Transmural myocardial infarction within the last 4 months prior to registration.
    • Functional Classification III/IV within 4 months prior to registration.
    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 4 months prior to registration
    • History of loss of consciousness or within 12 months prior to randomization
    • History of seizure disorder or condition that may predispose to seizure (e.g. prior cortical stroke or significant brain trauma)
    • History of uncontrolled hypertension defined as a sustained systolic blood pressure in excess of 150 mmHg or a sustained diastolic blood pressure in excess of 90 mmHg despite optimized antihypertensive therapy.
    • History of repeated falls and fractures over the past 12 months that in the opinion of the treating investigator would put the patient at risk for poor bone outcomes from androgen receptor targeted therapy
  • Known gastrointestinal disorder affecting absorption of oral medications.
  • Active uncontrolled infection defined as an identified infectious condition that requires active therapy that has not yet been completed.
  • positive patients with \< 200 cells/microliter within 30 days prior to registration OR HIV patients under treatment with highly active antiretroviral therapy (HAART) within 30 days prior to registration regardless of CD4 count. Note: HIV testing is not required for eligibility for this protocol as it is self-reported. This exclusion criterion is necessary because the treatments involved in this protocol may be and/or interact with HAART.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
188 participants (actual)

Study arms

  • Active comparator
    Salvage Radiation Therapy (SRT) + Standard androgen deprivation therapy (ADT)

    Standard ADT: 24 months of GnRH analog (any formulation) with optional 1-4 months of bicalutamide (50 mg/day). SRT: Starting within 0-70 days of initiation of GnRH analog, 66.6-70.2 Gy as 1.8 Gy/fraction in 37-39 fractions or 66.0-70.0 Gy as 2.0 Gy/fraction in 33-35 fractions lasting approximately 7-8 weeks, and optional lymph node boost.

    Radiation: Radiation Therapy · Drug: Bicalutamide · Drug: GnRH analog

  • Experimental
    Salvage Radiation Therapy + Enhanced ADT

    Enhanced ADT: 24 months of GnRH analog (any formulation) with 24 months of enzalutamide (160 mg/day). SRT: Starting within 0-70 days of initiation of GnRH analog, 66.6-70.2 Gy as 1.8 Gy/fraction in 37-39 fractions or 66.0-70.0 Gy as 2.0 Gy/fraction in 33-35 fractions lasting approximately 7-8 weeks, and optional lymph node boost.

    Radiation: Radiation Therapy · Drug: Enzalutamide · Drug: GnRH analog

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Alive Without Progression (Progression-Free Survival)

    Progression-free survival (PFS) is estimated by the Kaplan-Meier method. PFS time is measured from randomization to the date of first PFS failure (biochemical or clinical failure, initiation of new unplanned anticancer treatment, or death from any cause) or last known follow-up (censored). Analysis was to occur after progression or death was reported for 101 participants. Biochemical failure is defined as first post-RT detectable PSA (PSA ≥ 0.05). Clinical failure is defined as either a local, regional, or distant failure.

    Time frame: From randomization to first failure or last known follow-up. Median follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.

Secondary outcomes

  1. Percentage of Participants With Biochemical Failure

    Biochemical failure is defined as the first detectable post-RT prostate-specific antigen (PSA) value (≥ 0.05) or the initiation of salvage hormone therapy. Failure rates are estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis.

    Time frame: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.

  2. Percentage of Participants With Alternative Biochemical Failure

    Alternative biochemical failure is defined as first post-RT PSA ≥ 0.1 ng/mL or initiation of salvage hormone therapy. Failure rates are estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis.

    Time frame: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.

  3. Percentage of Participants With Hormone-refractory Disease

    Hormone-refractory disease is defined as three rises in PSA during salvage androgen deprivation, with the date determined as the midway date between the last non-rising PSA and the first of the three rises. Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.

    Time frame: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.

  4. Percentage of Participants With Distant Metastasis

    Distant failure is defined as first radiographic evidence of distant metastasis (e.g., bone scan, computed tomography (CT), magnetic resonance imaging (MRI)). Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.

    Time frame: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.

  5. Percentage of Participants With Prostate Cancer Death

    Cause-specific mortality is defined as death due to prostate cancer. Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.

    Time frame: From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.

  6. Percentage of Participants Alive (Overall Survival)

    Survival rates were to be estimated using the Kaplan-Meier method, censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only counts are provided. In this case, the number of participants without event (death), which is the number of participants alive.

    Time frame: From randomization to death or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.

  7. Change From Baseline to End of RT in the 5-level European Quality of Life Questionnaire (EQ-5D-5L) Index Score

    The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.

    Time frame: Baseline and end of radiation treatment (RT). End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.

  8. Change From Baseline to One Year After End of RT in the EQ-5D-5L Index Score

    The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.

    Time frame: Baseline and one year after end RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.

  9. Change From Baseline to Two Years After End of RT in the EQ-5D-5L Index Score

    The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.

    Time frame: Baseline and two years after end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.

  10. Change From Baseline to End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]

    The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.

    Time frame: Baseline and end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.

  11. Change From Baseline to One Year After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]

    The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.

    Time frame: Baseline and one year after end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.

  12. Change From Baseline to Two Years After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]

    The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.

    Time frame: Baseline, two years after end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.

  13. Number of Participants by Highest Grade Adverse Event Reported CTCAE v5

    Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.

    Time frame: From randomization to death or last known follow-up. Median follow-up time at the time of analysis was 33.1 months.

  14. Number of Participants Any Adverse Event Occuring Within 30 Days Following the End of Treatment

    Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.

    Time frame: From randomization to 30 days after the end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.

  15. Number of Participants With Any Grade 3+ Adverse Event Occuring After 30 Days Following the End of RT

    Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.

    Time frame: From 31 days after the end of RT to death or last known follow-up. Median follow-up was 33.1 months. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.

  16. Number of Participants With Post-baseline Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Scores ≥ 3

    PRO-CTCAE is a patient-reported outcome (PRO) measurement system developed to evaluate symptomatic toxicity in patients on cancer clinical trials, asking the patient about experience over the last seven days. Scores may reflect worst severity of the symptom (0=None, 1=Mild, 2=Moderate, 3=Severe, and 4=Very severe), frequency of the symptom (0=Never, 1=Rarely, 2=Occasionally, 3=Frequently, 4=Almost constantly), or the symptom's interference with one's "usual or daily activities" (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). The symptom row title will indicate "Severity", "Frequency", or "Interference". All scores are compared between arms; statistical analysis results are entered for p-values \< 0.05.

    Time frame: End of RT, one and two years after the end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.

07

Results

Posted Oct 16, 2024
Limitations and caveats
The sample size calculation was modified due to a change in eligibility, however the sample size itself remained the same at 242 patients since the hazard ratio was reduced of 0.65 to 0.63. Later, a change in the definition of biochemical failure which is a component of the primary endpoint of PFS decreased the sample size to 170 patients.

Participant flow

Participant flow — Overall Study
MilestoneSalvage Radiation Therapy (SRT) + Standard Androgen Deprivation Therapy (ADT)Salvage Radiation Therapy + Enhanced ADT
Started9890
Adverse event population9889
Completed9890
Not completed00

Outcome measures

PrimaryPercentage of Participants Alive Without Progression (Progression-Free Survival)

Progression-free survival (PFS) is estimated by the Kaplan-Meier method. PFS time is measured from randomization to the date of first PFS failure (biochemical or clinical failure, initiation of new unplanned anticancer treatment, or death from any cause) or last known follow-up (censored). Analysis was to occur after progression or death was reported for 101 participants. Biochemical failure is defined as first post-RT detectable PSA (PSA ≥ 0.05). Clinical failure is defined as either a local, regional, or distant failure.

Time frame:
From randomization to first failure or last known follow-up. Median follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.
Reported as:
Number · percentage of participants
Percentage of Participants Alive Without Progression (Progression-Free Survival)
percentage of participantsSRT + Standard ADTSRT + Enhanced ADT
1 year38.3 (32.0 to 44.7)45.5 (38.6 to 52.4)
2 years32.1 (26.0 to 38.2)38.3 (31.5 to 45.0)
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · Log Rank · p = 0.0671 · Hazard ratio (hr): 0.76 · 80% CI 0.61 to 0.96Reference level = standard ADT
SecondaryPercentage of Participants With Biochemical Failure

Biochemical failure is defined as the first detectable post-RT prostate-specific antigen (PSA) value (≥ 0.05) or the initiation of salvage hormone therapy. Failure rates are estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis.

Time frame:
From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.
Reported as:
Number · percentage of participants
Percentage of Participants With Biochemical Failure
percentage of participantsSRT + Standard ADTSRT + Enhanced ADT
1 year61.7 (51.1 to 70.6)54.6 (43.4 to 64.5)
2 years67.9 (57.5 to 76.3)60.6 (49.3 to 70.2)
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · Gray's · p = 0.1160 · Hazard ratio (hr): 0.75 · 95% CI 0.53 to 1.07Reference level = SRT + Standard ADT
SecondaryPercentage of Participants With Alternative Biochemical Failure

Alternative biochemical failure is defined as first post-RT PSA ≥ 0.1 ng/mL or initiation of salvage hormone therapy. Failure rates are estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis.

Time frame:
From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.
Reported as:
Number · percentage of participants
Percentage of Participants With Alternative Biochemical Failure
percentage of participantsSRT + Standard ADTSRT + Enhanced ADT
1 year35.9 (26.5 to 45.5)31.4 (21.9 to 41.3)
2 years45.4 (35.2 to 55.0)39.9 (29.4 to 50.2)
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · Gray's · p = 0.1618 · Hazard ratio (hr): 0.74 · 95% CI 0.50 to 1.12Reference level = SRT + Standard ADT
SecondaryPercentage of Participants With Hormone-refractory Disease

Hormone-refractory disease is defined as three rises in PSA during salvage androgen deprivation, with the date determined as the midway date between the last non-rising PSA and the first of the three rises. Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.

Time frame:
From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.
Reported as:
Count of participants · Participants
Percentage of Participants With Hormone-refractory Disease
ParticipantsSRT + Standard ADTSRT + Enhanced ADT
Percentage of Participants With Hormone-refractory Disease00
SecondaryPercentage of Participants With Distant Metastasis

Distant failure is defined as first radiographic evidence of distant metastasis (e.g., bone scan, computed tomography (CT), magnetic resonance imaging (MRI)). Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.

Time frame:
From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.
Reported as:
Count of participants · Participants
Percentage of Participants With Distant Metastasis
ParticipantsSRT + Standard ADTSRT + Enhanced ADT
Percentage of Participants With Distant Metastasis61
SecondaryPercentage of Participants With Prostate Cancer Death

Cause-specific mortality is defined as death due to prostate cancer. Failure rates were to be estimated using the cumulative incidence method, treating death as a competing risk, and otherwise censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only the counts of participants with the event are provided.

Time frame:
From randomization to first failure, competing event, or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.
Reported as:
Count of participants · Participants
Percentage of Participants With Prostate Cancer Death
ParticipantsSRT + Standard ADTSRT + Enhanced ADT
Percentage of Participants With Prostate Cancer Death00
SecondaryPercentage of Participants Alive (Overall Survival)

Survival rates were to be estimated using the Kaplan-Meier method, censoring participants alive at time of analysis, but for endpoints with \< 10 events overall, such as this one, only counts are provided. In this case, the number of participants without event (death), which is the number of participants alive.

Time frame:
From randomization to death or last known follow-up, whichever occurs first. Median follow-up time at the time of analysis was 33.1 months.
Reported as:
Count of participants · Participants
Percentage of Participants Alive (Overall Survival)
ParticipantsSRT + Standard ADTSRT + Enhanced ADT
Percentage of Participants Alive (Overall Survival)9690
SecondaryChange From Baseline to End of RT in the 5-level European Quality of Life Questionnaire (EQ-5D-5L) Index Score

The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.

Time frame:
Baseline and end of radiation treatment (RT). End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Reported as:
Mean · score on a scale
Change From Baseline to End of RT in the 5-level European Quality of Life Questionnaire (EQ-5D-5L) Index Score
score on a scaleSRT + Standard ADTSRT + Enhanced ADT
Change From Baseline to End of RT in the 5-level European Quality of Life Questionnaire (EQ-5D-5L) Index Score0.0 ± 0.10.0 ± 0.1
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · t-test, 2 sided · p = 0.7184
SecondaryChange From Baseline to One Year After End of RT in the EQ-5D-5L Index Score

The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.

Time frame:
Baseline and one year after end RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Reported as:
Mean · score on a scale
Change From Baseline to One Year After End of RT in the EQ-5D-5L Index Score
score on a scaleSRT + Standard ADTSRT + Enhanced ADT
Change From Baseline to One Year After End of RT in the EQ-5D-5L Index Score0.0 ± 0.10.0 ± 0.1
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · t-test, 2 sided · p = 0.5934
SecondaryChange From Baseline to Two Years After End of RT in the EQ-5D-5L Index Score

The EQ-5D-5L is a self-assessment questionnaire. The index score is computed from 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme). The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change score was calculated by subtracting baseline from later score, with a positive change score indicating improvement.

Time frame:
Baseline and two years after end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Reported as:
Mean · score on a scale
Change From Baseline to Two Years After End of RT in the EQ-5D-5L Index Score
score on a scaleSRT + Standard ADTSRT + Enhanced ADT
Change From Baseline to Two Years After End of RT in the EQ-5D-5L Index Score0.0 ± 0.10.0 ± 0.1
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · t-test, 2 sided · p = 0.7129
SecondaryChange From Baseline to End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]

The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.

Time frame:
Baseline and end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Reported as:
Mean · score on a scale
Change From Baseline to End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]
score on a scaleSRT + Standard ADTSRT + Enhanced ADT
Change From Baseline to End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]3.4 ± 7.86.8 ± 6.4
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · t-test, 2 sided · p = 0.006258
SecondaryChange From Baseline to One Year After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]

The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.

Time frame:
Baseline and one year after end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Reported as:
Mean · score on a scale
Change From Baseline to One Year After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]
score on a scaleSRT + Standard ADTSRT + Enhanced ADT
Change From Baseline to One Year After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]4.0 ± 7.47.0 ± 8.0
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · t-test, 2 sided · p = 0.0263
SecondaryChange From Baseline to Two Years After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]

The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible raw scores range from 29.4 to 83.2 (higher raw score indicating greater fatigue) and are converted into standardized T-scores (mean=50, standard deviation=10) with higher scores also indicating greater fatigue. Change score is calculated by subtracting baseline T-score from later T-score, with a positive change score indicating increased fatigue.

Time frame:
Baseline, two years after end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Reported as:
Mean · score on a scale
Change From Baseline to Two Years After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]
score on a scaleSRT + Standard ADTSRT + Enhanced ADT
Change From Baseline to Two Years After the End of RT in the 7-item Patient Reported Outcomes Measurement Information System - Fatigue Short Form (PROMIS-F SF 7a) [PROMIS Fatigue Score]4.0 ± 7.55.0 ± 7.8
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · t-test, 2 sided · p = 0.4599
SecondaryNumber of Participants by Highest Grade Adverse Event Reported CTCAE v5

Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.

Time frame:
From randomization to death or last known follow-up. Median follow-up time at the time of analysis was 33.1 months.
Reported as:
Count of participants · Participants
Number of Participants by Highest Grade Adverse Event Reported CTCAE v5
ParticipantsSRT + Standard ADTSRT + Enhanced ADT
None83
Grade 1199
Grade 23832
Grade 32739
Grade 466
Grade 500
SecondaryNumber of Participants Any Adverse Event Occuring Within 30 Days Following the End of Treatment

Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.

Time frame:
From randomization to 30 days after the end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Reported as:
Count of participants · Participants
Number of Participants Any Adverse Event Occuring Within 30 Days Following the End of Treatment
ParticipantsSRT + Standard ADTSRT + Enhanced ADT
Number of Participants Any Adverse Event Occuring Within 30 Days Following the End of Treatment8683
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · Regression, Logistic · p = 0.3138 · Odds ratio (or): 1.65 · 95% CI 0.62 to 4.41Reference level = SRT + Standard ADT
SecondaryNumber of Participants With Any Grade 3+ Adverse Event Occuring After 30 Days Following the End of RT

Common Terminology Criteria for Adverse Events (version 5) grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.

Time frame:
From 31 days after the end of RT to death or last known follow-up. Median follow-up was 33.1 months. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Any Grade 3+ Adverse Event Occuring After 30 Days Following the End of RT
ParticipantsSRT + Standard ADTSRT + Enhanced ADT
Number of Participants With Any Grade 3+ Adverse Event Occuring After 30 Days Following the End of RT2730
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · Chi-squared · p = 0.3889
SecondaryNumber of Participants With Post-baseline Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Scores ≥ 3

PRO-CTCAE is a patient-reported outcome (PRO) measurement system developed to evaluate symptomatic toxicity in patients on cancer clinical trials, asking the patient about experience over the last seven days. Scores may reflect worst severity of the symptom (0=None, 1=Mild, 2=Moderate, 3=Severe, and 4=Very severe), frequency of the symptom (0=Never, 1=Rarely, 2=Occasionally, 3=Frequently, 4=Almost constantly), or the symptom's interference with one's "usual or daily activities" (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). The symptom row title will indicate "Severity", "Frequency", or "Interference". All scores are compared between arms; statistical analysis results are entered for p-values \< 0.05.

Time frame:
End of RT, one and two years after the end of RT. End of RT can vary greatly depending on when it starts, which can be from 0 to 70 days from the start of ADT, and lasting 7-8 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Post-baseline Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Scores ≥ 3
ParticipantsSRT + Standard ADTSRT + Enhanced ADT
Taste Changes Severity38
Decreased Appetite Severity26
Decreased Appetite Interference24
Nausea Frequency88
Nausea Severity73
Constipation Severity139
Loose Stool Frequency3019
Abdominal Pain Frequency1914
Abdominal Pain Severity139
Abdominal Pain Interference107
Bowel Movement Control Frequency95
Bowel Movement Control Interference75
Racing Heartbeat Frequency56
Racing Heartbeat Severity31
Itchy Skin Severity103
Concentration Problems Severity911
Concentration Problems Interference1211
Memory Problems Severity711
Memory Problems Interference811
Headache Frequency129
Headache Severity59
Headache Interference56
Fatigue Severity2931
Fatigue Interference3134
Pain with Urination Severity46
Urinary Urgency Frequency3837
Urinary Urgency Interference2325
Frequent Urination Frequency4645
Frequent Urination Interference2524
Urine Control Loss Frequency3939
Urine Control Loss Interference2228
Erection Difficulty Severity4024
Ejaculation Problems Frequency2618
Decreased Sexual Interest Severity4233
Breast Tenderness Severity77
Hot Flashes Frequency5663
Hot Flashes Severity3244
Pain Frequency3533
Pain Severity2123
Pain Interference1623
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · t-test, 2 sided · p = 0.0461
  • SRT + Standard ADT vs SRT + Enhanced ADT · t-test, 2 sided · p = 0.0181
Post-hocPercentage of Participants Alive Without Progression (Progression-Free Survival) [Alternate Definition]

Progression-free survival (PFS) is estimated by the Kaplan-Meier method. PFS time is measured from randomization to the date of first PFS failure (biochemical or clinical failure, initiation of new unplanned anticancer treatment, or death from any cause) or last known follow-up (censored). Analysis was to occur after progression or death was reported for 101 participants. Biochemical failure is defined as first post-RT PSA ≥ 0.2. Clinical failure is defined as either a local, regional, or distant failure.

Time frame:
From randomization to first failure or last known follow-up. Medium follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.
Reported as:
Number · percentage of participants
Percentage of Participants Alive Without Progression (Progression-Free Survival) [Alternate Definition]
percentage of participantsSRT + Standard ADTSRT + Enhanced ADT
1 year87.5 (83.2 to 91.8)91.9 (88.1 to 95.6)
2 years78.8 (73.4 to 84.2)88.3 (83.8 to 92.7)
Statistical analysis
  • SRT + Standard ADT vs SRT + Enhanced ADT · Log Rank · p = 0.10 (one-sided p-value) · Hazard ratio (hr): 0.62 · 80% CI 0.42 to 0.91

Adverse events

Collected over Baseline to the date of last known follow-up. Maximum follow-up time was 40.1 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SRT + Standard ADT2/98 (2%)11/98 (11.2%)89/98 (90.8%)
SRT + Enhanced ADT0/90 (0%)17/89 (19.1%)87/89 (97.8%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventSRT + Standard ADTSRT + Enhanced ADT
HematuriaRenal and urinary disorders0/983/89
Heart failureCardiac disorders1/982/89
Lung infectionInfections and infestations0/982/89
SepsisInfections and infestations1/982/89
Acute kidney injuryRenal and urinary disorders0/982/89
AnemiaBlood and lymphatic system disorders2/981/89
LeukocytosisBlood and lymphatic system disorders0/981/89
Atrial fibrillationCardiac disorders0/981/89
Myocardial infarctionCardiac disorders1/981/89
Eye disorders - OtherEye disorders0/981/89
Most frequent other events
Showing 10 of 75
Most frequent other events
EventSRT + Standard ADTSRT + Enhanced ADT
Hot flashesVascular disorders72/9873/89
FatigueGeneral disorders70/9865/89
DiarrheaGastrointestinal disorders61/9848/89
Urinary incontinenceRenal and urinary disorders43/9830/89
Urinary frequencyRenal and urinary disorders39/9835/89
AnemiaBlood and lymphatic system disorders16/9833/89
Urinary urgencyRenal and urinary disorders36/9825/89
NauseaGastrointestinal disorders18/9828/89
HypertensionVascular disorders25/9828/89
ConstipationGastrointestinal disorders28/9825/89

Baseline characteristics

Randomized participants

Age, Continuous
Age, Continuous(years)SRT + Standard ADTSRT + Enhanced ADTTotal
Median65 (48 to 78)63 (47 to 77)64 (47 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)SRT + Standard ADTSRT + Enhanced ADTTotal
Female000
Male9890188
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SRT + Standard ADTSRT + Enhanced ADTTotal
Hispanic or Latino8412
Not Hispanic or Latino8982171
Unknown or Not Reported145
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SRT + Standard ADTSRT + Enhanced ADTTotal
American Indian or Alaska Native000
Asian033
Native Hawaiian or Other Pacific Islander000
Black or African American61521
White8567152
More than one race235
Unknown or Not Reported527
Baseline PSA
Baseline PSA(ng/mL)SRT + Standard ADTSRT + Enhanced ADTTotal
Median0.565 (0.11 to 9.56)0.785 (0.109 to 24.8)0.605 (0.109 to 24.8)
Pathologic T-Stage
Pathologic T-Stage(Participants)SRT + Standard ADTSRT + Enhanced ADTTotal
T2211536
T3224
T3a312859
T3b424385
T4224
Pathologic N-Stage
Pathologic N-Stage(Participants)SRT + Standard ADTSRT + Enhanced ADTTotal
N06363126
N1202141
NX15621
Gleason Score
Gleason Score(Participants)SRT + Standard ADTSRT + Enhanced ADTTotal
6101
7393473
811516
9465197
10101

2 further baseline measures are reported on the registry.

08

Study locations

108 sites

Showing the first 100 of 108 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr;211(4):518-525. doi: 10.1097/JU.0000000000003891. Epub 2024 Feb 29. PubMed 38421243 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Apr 2023, 47 months.

Results were first posted in Oct 2024, 1 year 6 months after primary completion.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's 47 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2019
First posted
Jan 18, 2019
StartActual
Apr 15, 2019
Primary completionActual
Apr 7, 2023
CompletionEst.
Sep 15, 2029
Results first posted
Oct 16, 2024
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03809000
Lead sponsor
RTOG Foundation, Inc.
Responsible party
Sponsor
First posted
Jan 18, 2019
Start date
Apr 15, 2019
Primary completion
Apr 7, 2023
Completion
Sep 15, 2029 (estimated)
Results posted
Oct 16, 2024
Last update
Dec 30, 2025

Study contacts

Edwin Posadas, MD
principal investigator · RTOG Foundation
Hiram Gay, MD
principal investigator · RTOG Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion